Synopsis
As fairness markets globally noticed a pointy correction this 12 months, PharmEasy shelved its IPO plans. In a candid interview, CEO Siddharth Shah opened up concerning the firm’s street forward, together with profitability plans, valuation mismatch, enterprise technique, and rumours about placing Thyrocare up on the market.
This time final 12 months, a health-tech unicorn was gearing as much as hit the general public markets. API Holdings Ltd, the guardian firm of PharmEasy, had filed draft papers for its INR6,250 crore preliminary public providing (IPO). The corporate was on a robust footing, because it had closed a pre-IPO funding spherical at USD5.6 billion valuation.One 12 months down, the situation has fully modified. PharmEasy’s chief government officer Siddharth Shah humbly admits he’s “dangerous at
Why ?
Unique Financial Occasions Tales, Editorials & Knowledgeable opinion throughout 20+ sectors
Inventory evaluation. Market Analysis. Business Traits on 4000+ Shares
Clear expertise with
Minimal Advertisements
Remark & Interact with ET Prime group 
Unique invitations to Digital Occasions with Business Leaders 
A trusted group of Journalists & Analysts who can greatest filter sign from noise
